118 related articles for article (PubMed ID: 15446795)
1. Prostate implant evaluation using tumour control probability--the effect of input parameters.
Haworth A; Ebert M; Waterhouse D; Joseph D; Duchesne G
Phys Med Biol; 2004 Aug; 49(16):3649-64. PubMed ID: 15446795
[TBL] [Abstract][Full Text] [Related]
2. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
3. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.
Zaider M; Zelefsky MJ; Lee EK; Zakian KL; Amols HI; Dyke J; Cohen G; Hu Y; Endi AK; Chui C; Koutcher JA
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1085-96. PubMed ID: 10863082
[TBL] [Abstract][Full Text] [Related]
4. Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy.
Her EJ; Reynolds HM; Mears C; Williams S; Moorehouse C; Millar JL; Ebert MA; Haworth A
Phys Med Biol; 2018 Jun; 63(13):135011. PubMed ID: 29799812
[TBL] [Abstract][Full Text] [Related]
5. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
6. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.
Levegrün S; Jackson A; Zelefsky MJ; Skwarchuk MW; Venkatraman ES; Schlegel W; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1064-80. PubMed ID: 11704332
[TBL] [Abstract][Full Text] [Related]
7. Assessment of i-125 prostate implants by tumor bioeffect.
Haworth A; Ebert M; Waterhouse D; Joseph D; Duchesne G
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1405-13. PubMed ID: 15275726
[TBL] [Abstract][Full Text] [Related]
8. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose.
Wang JZ; Li XA
Med Phys; 2003 Jan; 30(1):34-40. PubMed ID: 12557976
[TBL] [Abstract][Full Text] [Related]
10. Improved tumour control probability with MRI-based prostate brachytherapy treatment planning.
Dinkla AM; Pieters BR; Koedooder K; van Wieringen N; van der Laarse R; van der Grient JN; Rasch CR; Koning CC; Bel A
Acta Oncol; 2013 Apr; 52(3):658-65. PubMed ID: 23282111
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
12. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
Xiong W; Li J; Ma CM
Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
14. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment.
Strigari L; Orlandini LC; Andriani I; d'Angelo A; Stefanacci M; Di Nallo AM; Benassi M
Phys Med Biol; 2008 Sep; 53(18):5045-59. PubMed ID: 18723926
[TBL] [Abstract][Full Text] [Related]
15. Patient-specific voxel-level dose prescription for prostate cancer radiotherapy considering tumor cell density and grade distribution.
Zhao Y; Haworth A; Reynolds HM; Her EJ; Sun Y; Finnegan R; Rowshanfarzad P; Ebert MA
Med Phys; 2023 Jun; 50(6):3746-3761. PubMed ID: 36734620
[TBL] [Abstract][Full Text] [Related]
16. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer.
Lindsay PE; Moiseenko VV; Van Dyk J; Battista JJ
Phys Med Biol; 2003 Feb; 48(4):507-22. PubMed ID: 12630745
[TBL] [Abstract][Full Text] [Related]
17. Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.
Keall PJ; Webb S
Phys Med Biol; 2007 Jan; 52(1):291-302. PubMed ID: 17183142
[TBL] [Abstract][Full Text] [Related]
18. Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning.
Haworth A; Williams S; Reynolds H; Waterhouse D; Duchesne GM; Bucci J; Joseph D; Bydder S; Ebert M
Brachytherapy; 2013; 12(6):628-36. PubMed ID: 23871660
[TBL] [Abstract][Full Text] [Related]
19. Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer.
Thomann B; Sachpazidis I; Koubar K; Zamboglou C; Mavroidis P; Wiehle R; Grosu AL; Baltas D
Radiother Oncol; 2018 Apr; 127(1):62-67. PubMed ID: 29548559
[TBL] [Abstract][Full Text] [Related]
20. A systematic study of imaging uncertainties and their impact on 125I prostate brachytherapy dose evaluation.
Lindsay PE; Van Dyk J; Battista JJ
Med Phys; 2003 Jul; 30(7):1897-908. PubMed ID: 12906208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
